Patent: 8,663,656
✉ Email this page to a colleague
Summary for Patent: 8,663,656
| Title: | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
| Abstract: | A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages A4, ET 5 and lineage 3 of N. meningitidis serogroup B. Rather than consisting of a single antigen, the composition comprises a mixture of 10 or fewer purified antigens, and should not include complex or undefined mixtures of antigens such as outer membrane vesicles. Five protein antigens are used in particular: (1) a ‘NadA’ protein; (2) a ‘741’ protein; (3) a ‘936’ protein; (4) a ‘953’ protein; and (5) a ‘287’ protein. |
| Inventor(s): | Mariagrazia Pizza |
| Assignee: | GlaxoSmithKline Biologicals SA |
| Application Number: | US10/530,753 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,663,656
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Biologicals | BEXSERO | meningococcal group b vaccine | Injection | 125546 | 23-Jan-15 | ⤷ Start Trial | 2023-10-02 |
| Valeant Pharmaceuticals Luxembourg S.à.r.l. | SILIQ | brodalumab | Injection | 761032 | February 15, 2017 | ⤷ Start Trial | 2023-10-02 |
| Bausch Health Ireland, Limited | SILIQ | brodalumab | Injection | 761032 | 15-Feb-17 | ⤷ Start Trial | 2023-10-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
